Abstract
Demonstration of reproducibility and consistency of process and product quality is one of the most crucial issues in using transient gene expression (TGE) technology for biopharmaceutical development. In this study, we challenged the production consistency of TGE by expressing nine batches of recombinant IgG antibody in human embryonic kidney 293 cells to evaluate reproducibility including viable cell density, viability, apoptotic status, and antibody yield in cell culture supernatant. Product quality including isoelectric point, binding affinity, secondary structure, and thermal stability was assessed as well. In addition, major glycan forms of antibody from different batches of production were compared to demonstrate glycosylation consistency. Glycan compositions of the antibody harvested at different time periods were also measured to illustrate N-glycan distribution over the culture time. From the results, it has been demonstrated that different TGE batches are reproducible from lot to lot in overall cell growth, product yield, and product qualities including isoelectric point, binding affinity, secondary structure, and thermal stability. Furthermore, major N-glycan compositions are consistent among different TGE batches and conserved during cell culture time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdiche Y, Malashock D, Pinkerton A, Pons J (2008) Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 377(2):209–217
Alexander CG, Wanner R, Johnson CM, Breitsprecher D, Winter G, Duhr S, Baaske P, Ferguson N (2014) Novel microscale approaches for easy, rapid determination of protein stability in academic and commercial settings. BBA Proteins Proteom 1844(12):2241–2250
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50
Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM (2008a) Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 36(15):e96–e96
Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DL, Wurm FM (2008b) Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol Bioeng 101(1):182–189
Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, Derow E, Wurm FM (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 21(1):148–153. doi:10.1021/bp049830x
Cho MS, Yee H, Brown C, Mei B, Mirenda C, Chan S (2003) Versatile expression system for rapid and stable production of recombinant proteins. Biotechnol Prog 19(1):229–232. doi:10.1021/bp0255964
Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JH, Rosing H, Beijnen JH (2009) Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 20(11):2021–2033
de la Cruz Edmonds MC, Tellers M, Chan C, Salmon P, Robinson DK, Markusen J (2006) Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol 34(2):179–190
DrugBank (2016) About DrugBank. Publisher. http://www.drugbank.ca/about
EMA (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
Galbraith DJ, Tait AS, Racher AJ, Birch JR, James DC (2006) Control of culture environment for improved polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells. Biotechnol Prog 22(3):753–762
Girard P, Derouazi M, Baumgartner G, Bourgeois M, Jordan M, Jacko B, Wurm FM (2002) 100-liter transient transfection. Cytotechnology 38(1–3):15–21
Gutierrez-Granados S, Cervera L, Segura Mde L, Wolfel J, Godia F (2016) Optimized production of HIV-1 virus-like particles by transient transfection in CAP-T cells. Appl Microbiol Biotechnol 100(9):3935–3947. doi:10.1007/s00253-015-7213-x
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447):1757–1765
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32(1):40–51. doi:10.1038/nbt.2786
Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385–392
Jefferis R (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21(1):11–16
Jiang MS, Yang X, Esposito D, Nelson E, Yuan J, Hopkins RF, Broadt T, Xiao Z, Colantonio S, Prieto DA, Welch AR, Creekmore SP, Mitra G, Zhu J (2015) Mammalian cell transient expression, non-affinity purification, and characterization of human recombinant IGFBP7, an IGF-1 targeting therapeutic protein. Int Immunopharmacol 29(2):476–487. doi:10.1016/j.intimp.2015.10.008
Korman AJ, Srinivasan M, Wang C, Selby MJ, Chen B, Cardarelli JM (2006) Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics. Google Patents
Lee HJ, Pardridge WM (2003) Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem 14(3):546–553
Muller N, Derouazi M, Van Tilborgh F, Wulhfard S, Hacker DL, Jordan M, Wurm FM (2007) Scalable transient gene expression in Chinese hamster ovary cells in instrumented and non-instrumented cultivation systems. Biotechnol Lett 29(5):703–711. doi:10.1007/s10529-006-9298-x
Nallet S, Fornelli L, Schmitt S, Parra J, Baldi L, Tsybin YO, Wurm FM (2012) Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells. New Biotechnol 29(4):471–476. doi:10.1016/j.nbt.2012.02.003
Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM (2011) A simple high-yielding process for transient gene expression in CHO cells. J Biotechnol 153(1–2):22–26. doi:10.1016/j.jbiotec.2011.03.001
Raymond C, Tom R, Perret S, Moussouami P, L’Abbé D, St-Laurent G, Durocher Y (2011) A simplified polyethylenimine-mediated transfection process for large-scale and high-throughput applications. Methods 55(1):44–51
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP (2011) Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 71(6):2250–2259. doi:10.1158/0008-5472.can-10-2277
Suen KF, Turner MS, Gao F, Liu B, Althage A, Slavin A, Ou W, Zuo E, Eckart M, Ogawa T, Yamada M, Tuntland T, Harris JL, Trauger JW (2010) Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. Protein Expr Purif 71(1):96–102. doi:10.1016/j.pep.2009.12.015
Toyama A, Nakagawa H, Matsuda K, Sato T-A, Nakamura Y, Ueda K (2012) Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energy-resolved oxonium ion monitoring. Anal Chem 84(22):9655–9662
Tuvesson O, Uhe C, Rozkov A, Lullau E (2008) Development of a generic transient transfection process at 100 L scale. Cytotechnology 56(2):123–136. doi:10.1007/s10616-008-9135-2
Wulhfard S, Tissot S, Bouchet S, Cevey J, De Jesus M, Hacker DL, Wurm FM (2008) Mild hypothermia improves transient gene expression yields several fold in Chinese hamster ovary cells. Biotechnol Prog 24(2):458–465. doi:10.1021/bp070286c
Ye J, Kober V, Tellers M, Naji Z, Salmon P, Markusen JF (2009) High-level protein expression in scalable CHO transient transfection. Biotechnol Bioeng 103(3):542–551
Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30(5):1158–1170. doi:10.1016/j.biotechadv.2011.08.022
Zhu J (2013) Update on production recombinant therapeutic protein transient gene expression. Smithers Rapra, Shropshire, UK
Zustiak MP, Jose L, Xie Y, Zhu J, Betenbaugh MJ (2014) Enhanced transient recombinant protein production in CHO cells through the co-transfection of the product gene with Bcl-xL. Biotechnol J 9(9):1164–1174. doi:10.1002/biot.201300468
Acknowledgments
The project was supported by the Science and Technology Commission of Shanghai (Grant Nos. 15DZ0503700 and 14712400300) and partially supported by the Natural Science Foundation of China (Grant No. 81502969).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Ding, K., Han, L., Zong, H. et al. Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein. Appl Microbiol Biotechnol 101, 1889–1898 (2017). https://doi.org/10.1007/s00253-016-7973-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-016-7973-y